VEGFA and ovarian cancer: A number of studies have demonstrated a relation between high pre-operative baseline serum VEGF and poor prognosis in ovarian cancer in either univariate or multivariate analysis [14-16] and two studies, including the earlier results from our cohort, have demonstrated a similar prognostic relation in patients with recurrent disease prior to commencing bevacizumab treatment [17,18].